Good news: its temporary
Tuttolomondo A, Cirrincione A, Casuccio A, Del Cuore A, Daidone M, Di Chiara T, et al
Relevance of These Differences Though Retatrutide shares similar pharmacokinetic duration with semaglutide and tirzepatide, its clinical outcomes differ due to the additional glucagon receptor activity
This mechanistic overlap explains why combining them may not produce additive benefitsthe GLP-1 receptor agonist effect of Rybelsus is already maximal, and adding a DPP-4 inhibitor to preserve endogenous GLP-1 (which is already being mimicked by semaglutide) offers limited additional advantage
The second group ends up lighter but weaker, with a slower metabolism and a higher probability of regaining the weight
"Although the idea of injecting is a big step for some people, it's convenient, relatively painless, and once a week